Advances in Pharmacokinetics and Drug Interactions
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".
Deadline for manuscript submissions: 20 April 2026 | Viewed by 14672
Special Issue Editors
Interests: the development and application of disease-drug-trial models in the area of chronic progressive diseases; special patient populations; drug-drug interactions; pharmacokinetics
Interests: pharmacokinetics; special populations; pharmacometrics; quantitative pharmacology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pharmaceutics is announcing this Special Issue on “Advances in Pharmacokinetics and Drug Interactions” with the goal of exploring the latest developments and advancements in pharmacokinetics (PK), quantitative pharmacology, and drug–drug interactions. Great strides have been made towards furthering our understanding of pharmacokinetics and drug interactions with the development of more advanced modeling and simulation approaches. Quantitative pharmacology approaches are helpful for understanding drug absorption, distribution, metabolism, and excretion, predicting drug concentrations, assessing drug–drug interactions, and understanding the variability in drug response. By integrating PK models with pharmacodynamic (PD) models, we can further forecast drug effects on biomarkers or clinical endpoints.
Drug–drug interactions (DDIs) are a major concern in drug development and clinical practice. DDIs can escalate the frequency and severity of adverse events or elevate the risk of treatment failure. Early prediction of the likelihood and the magnitude of DDIs has become part of the assessment of a new drug’s safety profile during drug development. Mechanistic and physiological approaches enable researchers to anticipate drug behavior across patient populations. In this context, physiologically based pharmacokinetic modeling has been extensively used to assess DDIs and support new drug applications to regulatory agencies. Subsequently, simulations allow the identification of patient subgroups at a higher risk of therapeutic failure, drug interactions, or safety concerns. Once these differences are characterized, the PK model can be linked to response models to assess whether dose adjustments are needed and, in this case, to optimize dosing strategies. Further improvements in pharmacokinetics and drug interactions may enhance pharmacological efficacy, safety, and patient outcomes, enabling more customized and effective treatment interventions.
This Special Issue—“Advances in Pharmacokinetics and Drug Interactions”—aims to showcase recent progress in pharmacokinetics and drug interactions to explore drug behavior and therapeutic results. Potential topics include but are not limited to:
- PK(/PD), PBPK, QSP models of drugs;
- Optimization of dosing regimens;
- Static models to investigate DDI potential and mechanistic models to investigate and confirm DDI potential;
- In vitro–in vivo extrapolation in the context of DDI;
- Mechanisms of drug–drug or drug–xenobiotic interactions;
- Quantitative pharmacology approaches.
We cordially invite researchers from academia, industry, and government agencies working in related fields to submit their work. The Special Issue will undergo rigorous review and editing by leading experts in pharmacokinetics and drug metabolism, ensuring that the articles meet the highest standards of quality and relevance.
Based on your expertise in the field, we would be honored if you would consider our invitation. If you are interested in discussing the Issue further, please feel free to contact the guest editors:
Prof. Dr. Stephan Schmidt
Prof. Dr. Natalia V. De Moraes
Prof. Dr. Vanessa Bergamin Boralli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacokinetics
- drug interactions
- PBPK modeling
- drug delivery systems
- personalized medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
